The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this funding opportunity announcement (FOA) is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.
Letter of Intent Due Date(s): 30 days prior to the application due date.
Application Due Dates: Dec. 22, 2021; Feb. 9, 2022; June 9, 2022; Oct. 8, 2022; Feb 8, 2023; June 9, 2023; Oct 10, 2023; Feb 8, 2024; June 7, 2024; Oct. 10, 2024
PAR-22-030 Expiration Date October 11, 2024 per issuance of NOT-NS-24-020(Original Expiration Date: June 08, 2024 )